November 7, 2023 02:32 PM ESTUpdated 02:43 PM
Pharma

Ac­tivist in­vestor El­liott buys $1B+ stake in Bio­Marin as CEO change nears

Andrew Dunn

Senior Biopharma Correspondent

The ac­tivist in­vest­ing gi­ant El­liott In­vest­ment Man­age­ment has bought over a $1 bil­lion stake in Bio­Marin, a per­son fa­mil­iar with the mat­ter tells End­points News …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times